Idarucizumab for dabigatran reversal: A systematic review and meta-analysis of indications and outcomes.

S F B van der Horst,E S L Martens,P L den Exter,M H A Bos, T E van Mens,M V Huisman,F A Klok

Thrombosis research（2023）

Cited 1|Views1

No score

Abstract

Idarucizumab was mainly prescribed in the setting of bleeding. The reported hemostatic effectiveness was good, especially perioperatively, and the incidence of thromboembolic events was low. Patients with dabigatran-associated bleeding or requiring an urgent procedure nonetheless face a high mortality risk.

Translated text

Key words

Idarucizumab,Anticoagulant reversal agents,Dabigatran,Bleeding,Surgical procedure,Critical care,Meta-analysis

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined